SynAct Pharma
SynAct strengthens its patent portfolio
SynAct Pharma AB (publ) (“SynAct”) today announced that its recently acquired affiliate, TXP Pharma AG (“TXP”), was granted a patent in Canada related to “Alpha- and gamma-MSH analogues”. In addition, TXP’s patent application in another patent family relating to ”Exendin-4-analogues” has entered national phase in significant countries and regions worldwide.
TXP Pharma operates as a fully owned subsidiary and was recently acquired to strengthen SynAct Pharma’s position in autoimmune diseases.
Alpha- and gamma-MSH analogues are peptides based on modifications of endogenous ligands to the melanocortin receptors, that plays a pivotal role in resolution of inflammation. TXP has applied its Branched Amino Acid Probes (BAP) to these peptides, and the new patent in Canada belongs to a family, where patents have been issued in several countries and regions, including Europe, Japan, and USA.
The Exendin-4-analogues are currently not a strategic focus point for SynAct Pharma, but it demonstrates the versatility of the BAP-technology that is a key asset in TXP Pharma. The BAP-modification of peptides has a large potential in a variety of indications and for the development of novel drugs, including the melanocortin analogue TXP-11, the leading peptide drug candidate, and other melanocortin analogues developed by TXP Pharma.
The patent application will be evaluated by the individual authorities in a process that may vary from country to country, and will, if successful, result in granting of patents as a next step.
The information was submitted, through the agency of the contact person below, for publication at 07:00 a.m CEST on March 23, 2023
| Datum | 2023-03-23, kl 07:00 |
| Källa | MFN |
Hej Serverägare! Har du problem med troll och spam? Nu finns möjligheten att sätta en liten avgift, t.ex. 20kr, på discord invites och därmed stoppa många återkommande troll samtidigt som du tjänar lite pengar. Kolla in Invite Paywall.